Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $122.38 USD
Change Today -1.34 / -1.08%
Volume 1.3M
MNK On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

mallinckrodt plc (MNK) Snapshot

Open
$123.40
Previous Close
$123.72
Day High
$124.26
Day Low
$121.00
52 Week High
03/23/15 - $134.26
52 Week Low
04/21/14 - $59.84
Market Cap
14.3B
Average Volume 10 Days
1.3M
EPS TTM
$3.80
Shares Outstanding
116.5M
EX-Date
--
P/E TM
32.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for MALLINCKRODT PLC (MNK)

mallinckrodt plc (MNK) Related Businessweek News

View More BusinessWeek News

mallinckrodt plc (MNK) Details

Mallinckrodt public limited company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging. The Specialty Pharmaceuticals segment provides Acthar, an injectable biopharmaceutical drug for use in various indications, including neurology, rheumatology, nephrology, and pulmonology; Ofirmev and Xartemis XR for pain indications; EXALGO extended-release tablets to treat chronic pain; and GABLOFEN injections for use in the management of spasticity of cerebral or spinal origin. It also offers generics and active pharmaceutical ingredients (API), such as hydrocodone and hydrocodone-containing tablets, oxycodone and oxycodone-containing tablets, and methylphenidate HCl extended-release tablets, as well as biologics, medicinal opioids, synthetic controlled substances, acetaminophen products, and other active ingredients. The Global Medical Imaging segment provides contrast media and delivery systems comprising ioversol and gadoversetamide injections for diagnostic imaging applications under the Optiray and Optimark brand names with pre-filled syringes and power injectors to the hospitals and imaging centers. It also offers nuclear imaging products consisting of technetium-99m generators under the Ultra-Technekow DTE brand; cold kits; and Octreoscan kits for localization of tumors. The company markets its products to physicians, pharmacists, pharmacy buyers, specialty pharmacies, radiologists, and radiology technicians, as well as distributes its products to drug wholesalers, retail pharmacy chains, hospital networks, ambulatory surgical centers, and governmental agencies; sells and distributes APIs directly or through distributors to other pharmaceutical companies; and markets and distributes nuclear imaging products to radiopharmacies and hospitals. Mallinckrodt public limited company is based in Dublin, Ireland.

5,500 Employees
Last Reported Date: 11/25/14

mallinckrodt plc (MNK) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $905.8K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $605.1K
Senior Vice President of Global Operations
Total Annual Compensation: $1.4M
Senior Vice President and President of US Spe...
Total Annual Compensation: $400.0K
Chief Strategy Officer and Senior Vice Presid...
Total Annual Compensation: $449.2K
Compensation as of Fiscal Year 2014.

mallinckrodt plc (MNK) Key Developments

Mallinckrodt Intends to Offer Through Two of its Wholly-Owned Subsidiaries Approximately $1.2 Billion Aggregate Amount of Senior Unsecured Notes Due 2020 and 2025

Mallinckrodt announced that it intends to offer through two of its wholly-owned subsidiaries approximately $1.2 billion aggregate amount of senior unsecured notes due 2020 and 2025. The company intends to use the net proceeds to fund its previously announced acquisition of Compound Holdings II Inc. and its related expenses.

Mallinckrodt public limited company Presents at 2015 Deutsche Bank Pharma OneonOne Day, Mar-26-2015

Mallinckrodt public limited company Presents at 2015 Deutsche Bank Pharma OneonOne Day, Mar-26-2015 . Venue: JW Marriott Denver at Cherry Creek, 150 Clayton Lane, Denver, CO 80206, United States.

Mallinckrodt Seeks Acquisitions

Mark Trudeau, Chief Executive Officer of Mallinckrodt public limited company said, "We specifically and proactively continue to identify assets that we believe are undervalued, that fit within our strategic platforms, and so, we already have a pretty good idea about where we're going to go next. Ikaria and Inomax was one of the very important ones for us, but there are a whole range of additional assets that we've already identified, that we believe will fit, both financially and strategically, and we're pursuing those aggressively."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNK:US $122.38 USD -1.34

MNK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $93.34 USD -1.77
Guerbet €35.71 EUR -1.16
Hospira Inc $87.46 USD -0.21
Ion Beam Applications €22.77 EUR -0.63
Lannett Co Inc $64.89 USD -2.30
View Industry Companies
 

Industry Analysis

MNK

Industry Average

Valuation MNK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.9x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MALLINCKRODT PLC, please visit www.mallinckrodt.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.